Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Cook

Showing results (151-160 of 158) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 158 results.
BMJ Open|November 17, 2022
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trialKara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, et al.
BMC Cancer|June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trialStefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
Brain Communications|June 27, 2022
Distributed brain co-processor for tracking spikes, seizures and behaviour during electrical brain stimulationVladimir Sladky, Petr Nejedly, Filip Mivalt, et al.
The New England Journal of Medicine|December 13, 2017
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaMaría-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Lancet (London, England)|December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
Blood|September 6, 2018
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signatureMichael A Chapman, Jonathan Sive, John Ambrose, et al.
Blood|August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analysesSikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
Epilepsia|April 23, 2025
Updated classification of epileptic seizures: Position paper of the International League Against EpilepsySándor Beniczky, Eugen Trinka, Elaine Wirrell, et al.
Pageof 16

Showing results (151-160 of 158) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 158 results.
BMJ Open|November 17, 2022
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trialKara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, et al.
BMC Cancer|June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trialStefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
Brain Communications|June 27, 2022
Distributed brain co-processor for tracking spikes, seizures and behaviour during electrical brain stimulationVladimir Sladky, Petr Nejedly, Filip Mivalt, et al.
The New England Journal of Medicine|December 13, 2017
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaMaría-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Lancet (London, England)|December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
Blood|September 6, 2018
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signatureMichael A Chapman, Jonathan Sive, John Ambrose, et al.
Blood|August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analysesSikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
Epilepsia|April 23, 2025
Updated classification of epileptic seizures: Position paper of the International League Against EpilepsySándor Beniczky, Eugen Trinka, Elaine Wirrell, et al.
Pageof 16